New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment.
Affiliation
Department of Radiology, Cork University Hospital, Ireland.Issue Date
2014Keywords
MELANOMAIMMUNE DISORDER
Metadata
Show full item recordCitation
New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. 2014, 37 (6):351-3 Oncol Res TreatJournal
Oncology research and treatmentDOI
10.1159/000362614PubMed ID
24903767Abstract
Ipilimumab, a cytotoxic monoclonal antibody that inhibits cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), has been established as an effective therapy in the management of advanced melanoma. Immune-mediated adverse events are a common side effect.Item Type
ArticleLanguage
enISSN
2296-5262ae974a485f413a2113503eed53cd6c53
10.1159/000362614
Scopus Count
Collections
Related articles
- Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
- Authors: Reddy SB, Possick JD, Kluger HM, Galan A, Han D
- Issue date: 2017 Oct
- Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
- Authors: Tan I, Malinzak M, Salama AKS
- Issue date: 2018 Jul 31
- Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
- Authors: Graziani G, Tentori L, Navarra P
- Issue date: 2012 Jan
- Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
- Authors: Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli M, Altomonte M, Maio M
- Issue date: 2009 Aug
- Management of immune-related adverse events and kinetics of response with ipilimumab.
- Authors: Weber JS, Kähler KC, Hauschild A
- Issue date: 2012 Jul 20